These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Dermal-adipose lymphatic flap venous wrapping: A novel lymphaticovenous shunt method for progression of upper extremity lymphedema with severe lymphosclerosis.
    Author: Yamamoto T, Miyazaki T, Sakai H, Tsukuura R, Yamamoto N.
    Journal: J Vasc Surg Venous Lymphat Disord; 2023 May; 11(3):619-625.e2. PubMed ID: 36580998.
    Abstract:
    BACKGROUND: Upper extremity lymphedema (UEL) causes a significant deterioration in the quality of life of breast cancer survivors. Lymphaticovenous shunt creation will address the pathophysiology of obstructive UEL; however, its efficacy has been limited for those with UEL progression due to lymphosclerosis. In the present study, we evaluated the feasibility of a new lymphaticovenous shunt method for progression of UEL. METHODS: A total of 37 patients who had undergone dermal-adipose lymphatic flap venous wrapping (DALF-VW) for the treatment of UEL progression refractory to previous lymphaticovenular anastomosis were included. A DALF was created where indocyanine green lymphography had shown dermal backflow and was wrapped with a reflux-free recipient vein. The patients' medical records were reviewed to obtain the clinical and intraoperative findings. The patient and vessel characteristics and postoperative results were evaluated. RESULTS: A total of 37 patients with unilateral UEL were included. All DALF-VW procedures were performed under local infiltration anesthesia, with 98 shunts created in 37 limbs (2.6 shunts per limb). The diameter of the vein used for DALF-VW ranged from 1.7 to 3.3 mm (average, 2.39 mm). The operative time ranged from 25 to 139 minutes (average, 47.8 minutes). The differences in the lymphedema quality of life score (45.6 ± 21.1 vs 32.5 ± 21.1; P = .009), UEL index (131.4 ± 18.2 vs 123.1 ± 16.4; P = .042), and frequency of cellulitis (0.8 ± 1.3 vs 0.2 ± 0.5 times annually; P = .010) before and after DALF-VW were statistically significant. CONCLUSIONS: DALF-VW was effective for UEL progression that was refractory to previous lymphaticovenular anastomosis surgery. DALF-VW could be a useful option for UEL progression with severe lymphosclerosis.
    [Abstract] [Full Text] [Related] [New Search]